

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

1089 Selected Articles from This Issue

SMALL MOLECULE THERAPEUTICS

1091 **Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models**

AC Frank T. Zenke, Astrid Zimmermann, Christian Sirrenberg, Heike Dahmen, Vladimir Kirkin, Ulrich Pehl, Thomas Grombacher, Claudia Wilm, Thomas Fuchss, Christiane Amendt, Lyubomir T. Vassilev, and Andree Blaukat

1102 **Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers**

Mary L. Disis, Lauren R. Corulli, Ekram A. Gad, Marlese R. Koehnlein, Denise L. Cecil, Peter D. Senter, Shyra J. Gardai, and Nicole M. Okeley

1110 **Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance**

Margaret L. Dahn, Brianne M. Cruickshank, Ainsleigh J. Jackson, Cheryl Dean, Ryan W. Holloway, Steven R. Hall, Krysta M. Coyle, Hillary Maillet, David M. Waisman, Kerry B. Goralski, Carman A. Giacomantonio, Ian C.G. Weaver, and Paola Marcato

1123 **Inhibition of Importin β 1 Augments the Anticancer Effect of Agonistic Anti-Death Receptor 5 Antibody in TRAIL-resistant Tumor Cells**

Yuko Kojima, Takashi Nishina, Hiroyasu Nakano, Ko Okumura, and Kazuyoshi Takeda

1134 **Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells**

AC Daisuke Yamashita, Mutsuko Minata, Ahmed N. Ibrahim, Shinobu Yamaguchi, Vito Coviello, Joshua D. Bernstock, Shuko Harada, Richard A. Cerione, Bakhos A. Tannous, Concettina La Motta, and Ichiro Nakano

LARGE MOLECULE THERAPEUTICS

1148 **Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with *KRAS*-Mutated Colorectal Cancer**

Sanjay Goel, Allyson J. Ocean, Ruwan Y. Parakrama, Mohammad H. Ghalib, Imran Chaudhary, Umang Shah, Sengottuvel Viswanathan, Himanshu Kharkwal, Matthew Coffey, and Radhashree Maitra

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1157 **SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy**

Vincenza Conteduca, Sheng-Yu Ku, Loredana Puca, Megan Slade, Luisa Fernandez, Judy Hess, Rohan Bareja, Panagiotis J. Vlachostergios, Michael Sigouros, Juan Miguel Mosquera, Andrea Sboner, David M. Nanus, Olivier Elemento, Ryan Dittamore, Scott T. Tagawa, and Himisha Beltran

1165 **Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies**

AC Roman Groisberg, Jason Roszik, Anthony P. Conley, Alexander J. Lazar, Daniella E. Portal, David S. Hong, Aung Naing, Cynthia E. Herzog, Neeta Somaiah, Maria A. Zarzour, Shreyaskumar Patel, Robert E. Brown, and Vivek Subbiah

1173 **Anti-KIT DNA Aptamer for Targeted Labeling of Gastrointestinal Stromal Tumor**

Sudeep Banerjee, Hyunho Yoon, Mayra Yebra, Chih-Min Tang, Mara Gilardi, Jayanth S. Shankara Narayanan, Rebekah R. White, Jason K. Sicklick, and Partha Ray

TABLE OF CONTENTS

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

1183 **CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma**

Guillermo Flores, Joel H. Everett, Elissa A. Boguslawski, Brandon M. Oswald, Zachary B. Madaj, Ian Beddows, Sergey Dikalov, Marie Adams, Carleen A. Klumpp-Thomas, Susan M. Kitchen-Goosen, Scott E. Martin, Natasha J. Caplen, Lee J. Helman, and Patrick J. Grohar

1197 **Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma**
Lei Fan, Xiang Huang, Jing Chen, Kai Zhang, Yan-hong Gu, Jing Sun, and Shi-yun Cui

1210 **Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors**


AC John H. Strickler, Patricia LoRusso, Ravi Salgia, Yoon-Koo Kang, Chia Jui Yen, Chia-Chi Lin, Peter Ansell, Monica Motwani, Shekman Wong, Huibin Yue, Lan Wang, Edward Reilly, Daniel Afar, Louie Naumovski, and Ramesh K. Ramanathan

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

In this issue, Zenke and colleagues introduce a novel pharmacological DNA-PK inhibitor M3814 (peposertib). M3814 blocks the repair of DNA double strand breaks, potently sensitizes cancer cells to radiation and regresses human tumor in mouse models of radiation therapy. The image shows that M3814 effectively prolongs the life of radiation-induced double strand breaks in FaDu xenograft tumors when given orally to nude mice. The abundant nuclear staining of γ H2AX, as seen in this image, is indicative of unrepaired double strand breaks. Read the full article on page 1091.



Molecular Cancer Therapeutics

19 (5)

Mol Cancer Ther 2020;19:1089-1217.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/19/5>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/19/5>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.